TANG CAPITAL PARTNERS LP
CIK 1191935 · last filed 2024-09-18
TANG CAPITAL PARTNERS LP is a corporate insider who has filed 74 SEC Form 4 insider transactions across 15 companies since 2007. The most recent filing shows the insider bought $5.4M of OMIC on Sep 18, 2024. Across all open-market trades the lifetime net is +$232.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $19.4M across reported positions. The firm reports its address in San Diego, CA. 208 SEC filings were submitted jointly with TANG CAPITAL MANAGEMENT LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$19.36M
15
74
$232.31M
Filer Profile
SUITE 210
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Singular Genomics Systems, Inc. (OMIC) Delisted | 10%+ Owner | 340,000 | $20.01 | $6.80M | $5.42M | 1 | 2024-09-18 |
| RAIN | 10%+ Owner | 3,850,513 | $0.74 | $2.85M | $3.69M | 3 | 2023-12-18 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 4,299,852 | $1.48 | $6.36M | $491.3K | 1 | 2023-05-10 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | 10%+ Owner | 5,279,801 | $1.88 | $9.93M | $257.9K | 1 | 2023-03-14 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | 10%+ Owner | 9,849,224 | $6.22 | $61.26M | $129.62M | 11 | 2021-12-01 |
| APVO | 10%+ Owner | 1 | $1.82 | $2 | $23.94M | 3 | 2021-11-26 |
| Odonate Therapeutics, Inc. (ODT) Delisted | 10%+ Owner | 15,238,782 | $1.12 | $17.07M | $16.61M | 5 | 2020-09-30 |
| HRTX | 10%+ Owner | 8,532,156 | $0.32 | $2.69M | $33.28M | 3 | 2018-04-02 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 1,238,543 | $58.70 | $72.70M | $1.19M | 2 | 2013-10-28 |
| HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted | Director | 528,767 | — | — | $2.50M | 3 | 2010-05-26 |
| VNDA | 10%+ Owner | 2,715,852 | $5.09 | $13.82M | -$3.42M | 7 | 2010-01-19 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 6,040,136 | — | — | $12.95M | 7 | 2009-03-10 |
| NEOSE TECHNOLOGIES INC (NTEC) Delisted | 10%+ Owner | 0 | $9.63 | $0 | $520.7K | 8 | 2008-11-12 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 13,500 | — | — | $51.2K | 3 | 2008-10-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | 10%+ Owner | 211,383 | — | — | $5.22M | 3 | 2008-05-16 |
Recent Filings
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-18 | Singular Genomics Systems, Inc. (OMIC) Delisted | Buy (P) | +367,248 | $5.42M | EDGAR |
| 2024-02-14 | — | Other (J) | −13,184,400 | $0 | |
| 2023-12-18 | RAIN | Sell (S) | −521,919 | -$628.2K | EDGAR |
| 2023-10-13 | RAIN | Buy (P) | +852,435 | $837.1K | EDGAR |
| 2023-06-01 | RAIN | Buy (P) | +3,264,819 | $3.48M | EDGAR |
| 2023-05-10 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Buy (P) | +251,964 | $491.3K | EDGAR |
| 2023-03-14 | Jounce Therapeutics, Inc. (JNCE) Delisted | Buy (P) | +257,961 | $257.9K | EDGAR |
| 2021-12-01 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Sell (S) | −1,765,160 | -$6.94M | EDGAR |
| 2021-11-26 | APVO | Sell (S) | −2,764,008 | -$31.10M | EDGAR |
| 2021-11-22 | APVO | Sell (S) | −2,515,992 | -$19.50M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.